Domestic companies won the first trial of 12 patents

Trial decision on 4 out of 12 patent disputes filed this year, all successful

The toughest patent was Amgen's Otezla, 7 companies requested a trial

This year, domestic pharmaceutical companies have challenged 12 new patents.

 

In 4 out of 12 patent disputes, generic companies have won all of them, and the remaining 8 cases have yet to be tried.

 

According to the pharmaceutical industry on the 21st, a total of 12 patent disputes pending from January this year to this day.

 

Daewoong and Chong Kun Dang were the most active companies to attack original patents.

 

Each requested 4 patent trials.

 

Subsequently, it was found that Dongkoo Bio&Pharma, Dong-A ST, Mothers Pharm, CTC Bio, Aju, Chodang, Cosmax pharma, Penmix, and Huons requested two patent trials.

 

In addition, JW-Pharma, Kwang Dong, Daehan, Dongkwang, Myungin, Boryung, Arlico, Wooridul, Ildong, Choa, Taejoon, Theragenetex, Hana, Kolmar Korea, Hyundai, Whanin, and Huvist filed a patent trial one by one.

 

10 of 12 patents were owned by Global Pharmaceuticals.

 

The remaining two were one patent for Chong Kun Dang's GERD treatment Eso Duo.

 

Chong Kun Dang is a challenger in four other patent disputes and is defending two Eso Duo patent disputes.

 

A total of 4 cases were concluded of the 12 patent trials filed this year.

 

Generic companies won all four patent disputes (first trial).

 

In February of this year, the first patent dispute began this year when JW Life Sciences requested a trial to confirm the scope of passive rights to Pfizer's Precedex (Dexmedetomidine) formulation patent.

 

Daehan joined, too.

 

The KIPO took the side of JW Life Sciences in the first trial.

 

Currently, Pfizer has filed a suit to cancel the trial in the Patent Court of Korea in objection.

 

Subsequently, on the 20th of the same month, CTC Bio filed a trial to confirm the scope of passive rights to the patent for the formulation of Chong Kun Dang's GERD treatment,Eso Duo.

 

Aju and Chodang joined.

 

The three companies also challenged another formulation patent for Eso Duo in September.

 

However, Daewon and Sinil, which had challenged Eso Duo’s patent with them, voluntarily withdrew the judgment.

 

On the 28th of the same month, Myungin challenged Eisai's Crystalline Form Patent for'Fycompa film coated tab', a treatment for epilepsy.

 

A trial was filed with Whanin to confirm the scope of rights, and at the first trial, generic companies won.

 

In March, Theragenetex filed an invalidation trial for a patent for the use of Handok's osteoporosis treatment Bonviva.

 

The treatment is sold by Handok in Korea, but the patent right is in Roche.

 

Following Theragenetex, Choa, Wooridul, Arlico, Kolmar Korea, Huvist, Ildong, Hana, Hyundai, Dongkwang joined.

 

In the same month, Daewoong challenged two patents for the formulation of Belkyra, an injection drug for improving allergan's jaw fat.

 

When Allergan splits the existing formulation patents and registers two new patents for patent defense, it also filed a negative trial for confirmation of the scope of rights.

 

The dispute ended with the victory of Daewoong and Penmix.

 

On July 22, Taejun filed a trial to confirm the scope of passive rights to a patent for the formulation of Novartis' glaucoma treatment Simbrinza (Brimonidine tartrate/Brinzolamide).

 

The first trial is still in progress.

 

On the 31st of the same month, Boryung filed a trial for a passive confirmation of the scope of rights against Celgene's Pomalyst.

 

Kwang Dong joined, and the results of the first trial have not yet come out.

 

On September 29, Daewoong challenged the formulation and use patents of Amgen's psoriasis treatment Otezla (Apremilast) at the same time.

 

A trial for invalidation was requested for the use patent, and a trial to confirm the passive scope of rights was requested for the formulation patent.

 

When Daewoong challenged patent of Otezla, Dong-A ST, Chong Kun Dang, Dongkoo Bio&Pharma, Mothers, Huons, and Cosmax pharma joined.

 

The first trial is still in progress.

 

For the last time this year, Chong Kun Dang filed a judgment for passively confirming the scope of rights to material patent of Bayer's NOAC (new oral anticoagulant) Xarelto.

 

In the case of Xarelto, SK Chemicals and Hanmi overcame the formulation patent and received generic for exclusivity.

 

If Chong Kun Dang succeeds in material patent, it can release generics before SK Chemicals and Hanmi.